Covered recipient · General Payments record
SASHA COURTNEY DAVIS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$209.43
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $209.43 | 5 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $96.24 | 1 |
| Novocure Inc. | $60.43 | 1 |
| Karyopharm Therapeutics Inc. | $18.81 | 1 |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 1 |
| AbbVie Inc. | $16.33 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SASHA COURTNEY DAVIS
NPI 1194019075 · CMS profile ID 2378874
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
TYLER, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $209.43 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $16.33 | 11/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722144487 | CMS |
| Novocure Inc. | $60.43 | 09/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740699187 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727787363 | CMS |
| Karyopharm Therapeutics Inc. | $18.81 | 08/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751735349 | CMS |
| Celgene Corporation | $96.24 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727787383 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $91,150.24 | 16 |
| PY2024 | Principal investigator | $102,318.97 | 23 |
| PY2023 | Principal investigator | $167,396.92 | 32 |
| PY2022 | Principal investigator | $244,503.39 | 39 |
| PY2021 | Principal investigator | $409,588.59 | 46 |
| PY2020 | Principal investigator | $357,909.58 | 144 |
| PY2019 | Principal investigator | $105,582.24 | 109 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,487.15 | 12/31/2023 | Non-covered Recipient Entity Texas Oncology-Tyler | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 | No dispute reported | 06/30/2026 | 1042504373 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,769.65 | 12/31/2023 | Non-covered Recipient Entity Texas Oncology-Tyler | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 | No dispute reported | 06/30/2026 | 1042504383 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,000.00 | 10/30/2023 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040058725 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,500.00 | 10/30/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040059295 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,650.00 | 10/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 991130245 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $48.60 | 10/09/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY - LONGVIEW CANCER CENTER | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017224553 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,507.99 | 10/09/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017227011 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $48.60 | 10/09/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY PALESTINE CANCER CENTER | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017243247 |
| Principal investigator 1 | Genentech, Inc. | $2,576.00 | 09/07/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040579283 |
| Principal investigator 1 | Genentech, Inc. | $1,938.00 | 08/17/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040578461 |
| Principal investigator 1 | Genentech, Inc. | $6,651.00 | 08/17/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040579067 |
| Principal investigator 1 | Genentech, Inc. | $1,145.00 | 08/17/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040579201 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,500.00 | 07/27/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040059255 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,063.00 | 07/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017227155 |
| Principal investigator 1 | Veru Inc. | $975.00 | 07/13/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | VERU001_V2000701_80052317 | No dispute reported | 06/30/2026 | 1058357419 |
| Principal investigator 1 | Veru Inc. | $10,029.04 | 06/16/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | VERU001_V2000701_80052317 | No dispute reported | 06/30/2026 | 1058356801 |
| Principal investigator 1 | Genentech, Inc. | $41,500.00 | 06/06/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040579421 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 06/05/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040578677 |
| Principal investigator 1 | Genentech, Inc. | $470.00 | 06/05/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040579885 |
| Principal investigator 1 | Genentech, Inc. | $724.00 | 06/05/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040580051 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,500.00 | 06/01/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040059031 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,500.00 | 04/24/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040059083 |
| Principal investigator 1 | Eli Lilly and Company | $0.04 | 04/19/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+ HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1038155037 |
| Principal investigator 1 | Eli Lilly and Company | $3,186.00 | 04/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+ HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1038155029 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $850.00 | 04/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | No dispute reported | 06/30/2026 | 1017222665 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,816.00 | 04/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017222825 |
| Principal investigator 1 | Genentech, Inc. | $6,600.00 | 03/23/2023 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1040578509 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,500.00 | 01/30/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | No dispute reported | 06/30/2026 | 1040059165 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/21/2023 | Non-covered Recipient Entity US Oncology LLC | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY | No dispute reported | 06/30/2026 | 1046534513 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,380.60 | 01/15/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY SOUTHWEST FORT WORTH | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 991124809 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,591.25 | 01/10/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy | No dispute reported | 06/30/2026 | 1017206869 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $890.00 | 01/01/2023 | Non-covered Recipient Entity TEXAS ONCOLOGY TYLER PHARMACY | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | No dispute reported | 06/30/2026 | 1017208087 |